机构:[1]Department of Pharmacology of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou,China广东省中医院[2]The Postdoctoral Research Station, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China[3]The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[4]Department of Pathology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China大德路总院珠海院区病理科病理科大德路总院病理科广东省中医院深圳市中医院深圳医学信息中心[5]Traditional Chinese Medicine Material Basic Research Team, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[6]Department of Chemical Research and Structural Optimization based on Chinese Material Medicine, The Second Affiliated Hospital of Guangzhou Universityof Chinese Medicine, Guangzhou, China[7]Department of Dermatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China大德路总院皮肤科大德路总院皮肤科广东省中医院
The discovery of new therapeutic drugs with the efficacious and safe ability to prevent epidermal hyperplasia is extremely urgent for psoriasis. Cryptotanshinone (CTS), an active component isolated from the root of Salvia miltiorrhiza Bunge, has been reported to have antibacterial and antitumor effects. However, its effects on psoriasis have not been reported. Here, we investigated the therapeutic effects of CTS on imiquimod (IMQ)-induced psoriatic-like skin model and explored the underlying mechanisms. Our results revealed that CTS effectively alleviates IMQ-induced epidermal hyperplasia. In vitro studies also indicated that CTS potently inhibits the growth of keratinocytes. We further found that STAT3, a transcription factor for the cell growth, is the key mediator of CTS on the proliferation of keratinocytes. Taken together, our findings indicated that the curative effects of CTS on psoriasis are accomplished mainly through modulating STAT3, which providing evidences to develop CTS as a potential therapeutic agent for patients with psoriasis.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81602748, 81302868]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2016A030310291, 2017A030313639]; TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine [YN2014ZH08, YN2015QN03]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2017M612639]; Medical Scientific Research Foundation of Guangdong Province [A2017277]
第一作者机构:[1]Department of Pharmacology of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou,China[2]The Postdoctoral Research Station, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Pharmacology of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou,China[4]Department of Pathology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China[7]Department of Dermatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China[*1]Department of Pharmacology of Traditional Chinese Medicine and Pathology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
推荐引用方式(GB/T 7714):
Tang Lipeng,He Songmin,Wang Xieqi,et al.Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3[J].EXPERIMENTAL DERMATOLOGY.2018,27(3):268-275.doi:10.1111/exd.13511.
APA:
Tang, Lipeng,He, Songmin,Wang, Xieqi,Liu, Hongying,Zhu, Ying...&Zheng, Guangjuan.(2018).Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3.EXPERIMENTAL DERMATOLOGY,27,(3)
MLA:
Tang, Lipeng,et al."Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3".EXPERIMENTAL DERMATOLOGY 27..3(2018):268-275